Radiopharmaceutical cancer treatment Lutathera® now available to Ontario patients with midgut neuroendocrine tumours (NETs).
The Ontario funding criteria covers the treatment of adult patients with somatostatin receptor-positive (SSR+) midgut NETs whose disease has progressed on a somatostatin analogue and is unresectable (not treatable by surgery). Eligible patients include those with progressed SSR+ midgut (defined as jejunoileum and proximal in the NETTER-1 trial) NETs and good performance status.
AAA press release:
ENGLISH – can be viewed at http://www.newswire.ca/en/releases/archive/October2020/08/c9204.html
FRENCH – can be viewed at http://www.newswire.ca/fr/releases/archive/October2020/08/c5664.html